Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Henry Schein Inc filings on SEC EDGAR ↗
Henry Schein announced a voluntary change to its non-GAAP financial reporting to exclude acquisition-related remeasurement gains starting in Q4 2026. Consequently, the company updated its FY2026 non-GAAP diluted EPS guidance to $5.42-$5.48 from $5.50-$5.56 to reflect this accounting adjustment, with no change to its underlying business outlook.
Henry Schein, Inc. reported net sales of $3.5 billion for the third quarter of 2026, a 4.0% increase compared to the prior year. Net income attributable to the company rose to $119 million, or $1.06 per diluted share, driven by higher gross profits and a reduction in restructuring costs.
Henry Schein reported Q3 2026 financial results with total sales of $3.5 billion, representing 4.0% growth driven by strong U.S. dental merchandise volume. The company raised its full-year 2026 non-GAAP diluted EPS guidance to a range of $5.50 to $5.56, citing strong operating performance and net tariff refund benefits.
Term
Q3 2026
“We delivered another strong quarter that increases our confidence in the momentum we are building at Henry Schein. I am very pleased with the U.S. dental merchandise sales growth of 8.6% driven primarily by volume in a stable market and our 19% adjusted earnings per share growth.”
Fred Lowery, Chief Executive Officer of Henry Schein
“Our strategy is translating into stronger financial results. We are gaining share in key businesses, improving our portfolio mix, maintaining a disciplined approach to capital allocation, and realizing the benefits of our value creation initiatives.”
Fred Lowery, Chief Executive Officer of Henry Schein